Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC
Background The necessity of platinum-doublet chemotherapy in first-line immunotherapy for non-squamous non-small cell lung cancer (nsqNSCLC) with programmed death-ligand 1 (PD-L1) expression on less than 50% of tumor cells remains poorly investigated. Biomarkers predicting this necessity can guide c...
Saved in:
| Main Authors: | Hui Li, Liang Zhang, Yu Xu, Jingjing Liu, Guoqiang Wang, Ying Cheng, Shangli Cai, Xinyue Wang, Peng Cui, Shaowei Lan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/11/e009693.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
by: Benjamin Besse, et al.
Published: (2016-04-01) -
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
by: Jian Wang, et al.
Published: (2020-05-01) -
Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC
by: Hong Liu, et al.
Published: (2024-12-01) -
Correction: Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Published: (2020-10-01) -
Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC
by: Xin Zheng, et al.
Published: (2024-12-01)